Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy

被引：17
|
作者：
Pol, Jonathan [1 ,2 ,3 ,4 ]
Kroemer, Guido [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Ctr Rech Cordeliers, INSERM U1138, Equipe Labelisee Ligue Natl Canc 11, F-75006 Paris, France
[2] Univ Paris 05, Sorbonne Paris Cite, F-75006 Paris, France
[3] Univ Paris 06, F-75006 Paris, France
[4] Metabol & Cell Biol Platforms, Gustave Roussy Canc Campus, F-94805 Villejuif, France
[5] Hop Europeen Georges Pompidou, Pole Biol, F-75015 Paris, France
[6] Karolinska Univ Hosp, Karolinska Inst, Dept Womens & Childrens Hlth, S-17176 Stockholm, Sweden
来源：
CELL RESEARCH | 2018年 / 28卷 / 05期
关键词：
REGULATORY T-CELLS; CANCER; ANTIBODIES; IPILIMUMAB; MELANOMA; THERAPY;
D O I：
10.1038/s41422-018-0031-9
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
A CTLA-4-specific antibody, ipilimumab, is clinically used in anticancer immunotherapy, yet induces severe autoimmune side effects. Two papers by Du et al. published recently in Cell Research now suggest strategies for potentially uncoupling toxicity and efficacy of CTLA-4-targeting antibodies.
引用
收藏
页码：501 / 502
页数：2
相关论文
共 50 条
  • [1] Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy
    Jonathan Pol
    Guido Kroemer
    Cell Research, 2018, 28 : 501 - 502
  • [2] Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity
    Marabelle, Aurelien
    Kohrt, Holbrook
    Levy, Ronald
    CLINICAL CANCER RESEARCH, 2013, 19 (19) : 5261 - 5263
  • [3] Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
    Babamohamadi, Mehregan
    Mohammadi, Nastaran
    Faryadi, Elham
    Haddadi, Maryam
    Merati, Amirhossein
    Ghobadinezhad, Farbod
    Amirian, Roshanak
    Izadi, Zhila
    Hadjati, Jamshid
    CELL DEATH & DISEASE, 2024, 15 (01) : 17
  • [4] Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
    Mehregan Babamohamadi
    Nastaran Mohammadi
    Elham Faryadi
    Maryam Haddadi
    Amirhossein Merati
    Farbod Ghobadinezhad
    Roshanak Amirian
    Zhila Izadi
    Jamshid Hadjati
    Cell Death & Disease, 15
  • [5] Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety
    Seeruttun, Sharvesh Raj
    AIMS GENETICS, 2019, 6 (03): : 64 - 66
  • [6] Uncoupling Therapeutic from Immunotherapy-related Adverse Effects for Safer and Effective Anti-CTLA-4 Antibodies in CTLA4 Humanized Mice
    Liu, Mingyue
    Du, Xuexiang
    Su, Juanjuan
    Zhang, Peng
    Liu, Yang
    Zheng, Pan
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 81 : 60 - 60
  • [7] Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
    Du, Xuexiang
    Liu, Mingyue
    Su, Juanjuan
    Zhang, Peng
    Tang, Fei
    Ye, Peiying
    Devenport, Martin
    Wang, Xu
    Zhang, Yan
    Liu, Yang
    Zheng, Pan
    CELL RESEARCH, 2018, 28 (04) : 433 - 447
  • [8] Uncoupling Therapeutic from Immunotherapy-related Adverse Effects for Safer and Effective Anti-CTLA-4 Antibodies in CTLA4 Humanized Mice
    Du, Xuexiang
    Tang, Fei
    Liu, Mingyue
    Liu, Yang
    Zheng, Pan
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [9] Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
    Xuexiang Du
    Mingyue Liu
    Juanjuan Su
    Peng Zhang
    Fei Tang
    Peiying Ye
    Martin Devenport
    Xu Wang
    Yan Zhang
    Yang Liu
    Pan Zheng
    Cell Research, 2018, 28 : 433 - 447
  • [10] Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy
    Rogiers, Aljosja
    Dimitriou, Florentia
    Lobon, Irene
    Harvey, Catriona
    Vergara, Ismael A.
    da Silva, Ines Pires
    Lo, Serigne N.
    Scolyer, Richard A.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Long, Georgina V.
    EUROPEAN JOURNAL OF CANCER, 2024, 198
12345